| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 15 | 2019 | 303 | 4.450 |
Why?
|
| Heart-Assist Devices | 11 | 2018 | 763 | 2.870 |
Why?
|
| Shock, Cardiogenic | 6 | 2024 | 107 | 2.640 |
Why?
|
| Heart Arrest | 13 | 2018 | 277 | 2.130 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2017 | 132 | 2.090 |
Why?
|
| Septal Occluder Device | 11 | 2020 | 45 | 2.050 |
Why?
|
| Ventricular Fibrillation | 10 | 2016 | 68 | 1.900 |
Why?
|
| Myocardial Infarction | 9 | 2024 | 375 | 1.880 |
Why?
|
| Myocardial Ischemia | 7 | 2024 | 162 | 1.800 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2019 | 222 | 1.770 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2023 | 178 | 1.600 |
Why?
|
| Coronary Vessels | 8 | 2024 | 192 | 1.520 |
Why?
|
| Echocardiography, Transesophageal | 11 | 2020 | 348 | 1.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2019 | 184 | 1.510 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2019 | 69 | 1.490 |
Why?
|
| Ventricular Function, Left | 7 | 2021 | 607 | 1.460 |
Why?
|
| Coronary Angiography | 15 | 2024 | 242 | 1.440 |
Why?
|
| Popliteal Artery | 2 | 2020 | 28 | 1.400 |
Why?
|
| Heart Failure | 9 | 2021 | 1191 | 1.380 |
Why?
|
| Absorbable Implants | 2 | 2020 | 35 | 1.370 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 96 | 1.340 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 96 | 1.270 |
Why?
|
| Treatment Outcome | 35 | 2024 | 8218 | 1.240 |
Why?
|
| Ischemia | 2 | 2020 | 252 | 1.210 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2019 | 479 | 1.060 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2020 | 64 | 1.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 8 | 2012 | 66 | 1.010 |
Why?
|
| Endothelin-1 | 3 | 2011 | 40 | 1.010 |
Why?
|
| Aortic Valve | 4 | 2023 | 244 | 1.000 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 144 | 0.960 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2020 | 93 | 0.950 |
Why?
|
| Ultrasonography, Interventional | 3 | 2023 | 124 | 0.940 |
Why?
|
| Coronary Artery Disease | 6 | 2024 | 364 | 0.940 |
Why?
|
| Stents | 5 | 2024 | 409 | 0.910 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 82 | 0.870 |
Why?
|
| Male | 55 | 2024 | 42488 | 0.860 |
Why?
|
| Hemodynamics | 6 | 2024 | 731 | 0.850 |
Why?
|
| Prosthesis Design | 7 | 2019 | 298 | 0.820 |
Why?
|
| Echocardiography, Three-Dimensional | 6 | 2020 | 518 | 0.800 |
Why?
|
| Pulmonary Embolism | 6 | 2021 | 229 | 0.800 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 200 | 0.760 |
Why?
|
| Humans | 70 | 2024 | 89613 | 0.760 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 288 | 0.760 |
Why?
|
| Thrombolytic Therapy | 5 | 2021 | 238 | 0.750 |
Why?
|
| Catheterization | 4 | 2017 | 237 | 0.730 |
Why?
|
| Middle Aged | 29 | 2024 | 26012 | 0.730 |
Why?
|
| Aged | 28 | 2024 | 19158 | 0.690 |
Why?
|
| Registries | 5 | 2020 | 791 | 0.630 |
Why?
|
| Retrospective Studies | 21 | 2023 | 9127 | 0.610 |
Why?
|
| Hospital Costs | 1 | 2019 | 109 | 0.610 |
Why?
|
| Female | 39 | 2024 | 46401 | 0.590 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 30 | 0.590 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 60 | 0.590 |
Why?
|
| Coronary Artery Bypass | 3 | 2023 | 236 | 0.590 |
Why?
|
| Clinical Protocols | 1 | 2018 | 158 | 0.580 |
Why?
|
| Balloon Occlusion | 3 | 2012 | 29 | 0.580 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 41 | 0.580 |
Why?
|
| Heart Ventricles | 2 | 2020 | 779 | 0.580 |
Why?
|
| Arteriovenous Fistula | 1 | 2018 | 53 | 0.580 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 153 | 0.570 |
Why?
|
| Blood Circulation | 1 | 2017 | 30 | 0.570 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.570 |
Why?
|
| Venae Cavae | 1 | 2017 | 12 | 0.570 |
Why?
|
| Swine | 13 | 2016 | 588 | 0.570 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 24 | 0.570 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 126 | 0.570 |
Why?
|
| Aminophylline | 1 | 2016 | 14 | 0.560 |
Why?
|
| Device Removal | 1 | 2018 | 168 | 0.560 |
Why?
|
| Bradycardia | 1 | 2016 | 40 | 0.550 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 32 | 0.550 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 223 | 0.540 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 116 | 0.540 |
Why?
|
| Dyspnea | 1 | 2016 | 76 | 0.530 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 265 | 0.530 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 219 | 0.530 |
Why?
|
| Balloon Valvuloplasty | 1 | 2015 | 8 | 0.520 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 27 | 0.520 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2297 | 0.520 |
Why?
|
| Disease Management | 1 | 2018 | 326 | 0.510 |
Why?
|
| Vascular Fistula | 1 | 2015 | 12 | 0.510 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 98 | 0.500 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 145 | 0.500 |
Why?
|
| Fontan Procedure | 1 | 2015 | 56 | 0.490 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 136 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1050 | 0.490 |
Why?
|
| Ventricular Septum | 1 | 2014 | 14 | 0.480 |
Why?
|
| Heart Injuries | 1 | 2014 | 19 | 0.480 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 93 | 0.470 |
Why?
|
| Electrocardiography | 4 | 2012 | 497 | 0.470 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 70 | 0.470 |
Why?
|
| Epinephrine | 2 | 2011 | 89 | 0.460 |
Why?
|
| Adenosine | 1 | 2016 | 238 | 0.450 |
Why?
|
| Time Factors | 10 | 2021 | 5337 | 0.450 |
Why?
|
| Aneurysm, False | 1 | 2014 | 54 | 0.450 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2015 | 103 | 0.440 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 89 | 0.420 |
Why?
|
| Risk Assessment | 8 | 2020 | 2304 | 0.410 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 263 | 0.400 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 18 | 0.400 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 365 | 0.400 |
Why?
|
| Biomarkers | 3 | 2019 | 1768 | 0.380 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 171 | 0.380 |
Why?
|
| Thymosin | 1 | 2011 | 6 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6771 | 0.370 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 16 | 0.370 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.370 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 52 | 0.360 |
Why?
|
| Electric Countershock | 2 | 2011 | 55 | 0.360 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 161 | 0.350 |
Why?
|
| Coronary Disease | 2 | 2012 | 260 | 0.350 |
Why?
|
| Vascular Patency | 2 | 2020 | 129 | 0.340 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 188 | 0.340 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2384 | 0.330 |
Why?
|
| Mitral Valve | 3 | 2020 | 262 | 0.330 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 238 | 0.330 |
Why?
|
| After-Hours Care | 1 | 2008 | 8 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 405 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1851 | 0.310 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 14 | 0.300 |
Why?
|
| Medical Errors | 1 | 2008 | 115 | 0.290 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.290 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2020 | 192 | 0.290 |
Why?
|
| Coronary Circulation | 3 | 2024 | 131 | 0.290 |
Why?
|
| Hypoxia | 1 | 2012 | 656 | 0.280 |
Why?
|
| Risk Factors | 8 | 2021 | 5517 | 0.280 |
Why?
|
| United States | 7 | 2020 | 7050 | 0.280 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3659 | 0.270 |
Why?
|
| Thrombectomy | 1 | 2008 | 189 | 0.260 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1727 | 0.260 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 304 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 224 | 0.250 |
Why?
|
| Artifacts | 1 | 2007 | 246 | 0.250 |
Why?
|
| Adult | 11 | 2024 | 26704 | 0.250 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 433 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 377 | 0.240 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 79 | 0.240 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 332 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 61 | 0.230 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 92 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 465 | 0.230 |
Why?
|
| Heart Transplantation | 2 | 2023 | 717 | 0.220 |
Why?
|
| Carotid Arteries | 1 | 2024 | 135 | 0.220 |
Why?
|
| Cysteine | 1 | 2024 | 137 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2016 | 298 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2008 | 791 | 0.210 |
Why?
|
| Microcirculation | 2 | 2024 | 104 | 0.200 |
Why?
|
| Ulnar Artery | 1 | 2022 | 5 | 0.200 |
Why?
|
| Survival Rate | 5 | 2019 | 1887 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1394 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 699 | 0.200 |
Why?
|
| Radial Artery | 1 | 2022 | 33 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 714 | 0.200 |
Why?
|
| Stroke Volume | 3 | 2021 | 465 | 0.190 |
Why?
|
| Aorta | 2 | 2020 | 289 | 0.190 |
Why?
|
| Pilot Projects | 1 | 2024 | 870 | 0.190 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1983 | 0.180 |
Why?
|
| Acute Disease | 3 | 2021 | 842 | 0.180 |
Why?
|
| Transillumination | 1 | 2020 | 9 | 0.180 |
Why?
|
| Limb Salvage | 1 | 2020 | 35 | 0.180 |
Why?
|
| Reoperation | 2 | 2013 | 603 | 0.180 |
Why?
|
| Ultrasonography | 3 | 2015 | 714 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 12 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 85 | 0.170 |
Why?
|
| Recovery of Function | 2 | 2018 | 293 | 0.170 |
Why?
|
| Resuscitation | 2 | 2011 | 110 | 0.170 |
Why?
|
| Animals | 14 | 2016 | 27481 | 0.170 |
Why?
|
| Coronary Restenosis | 3 | 2010 | 11 | 0.160 |
Why?
|
| Fluoroscopy | 1 | 2019 | 123 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 252 | 0.160 |
Why?
|
| Saphenous Vein | 2 | 2010 | 61 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 144 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 220 | 0.150 |
Why?
|
| Microvessels | 1 | 2018 | 69 | 0.150 |
Why?
|
| Echocardiography | 4 | 2020 | 939 | 0.150 |
Why?
|
| Recurrence | 2 | 2012 | 1143 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 276 | 0.140 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Triage | 1 | 2018 | 113 | 0.140 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 6 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 6 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 257 | 0.140 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 14 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 149 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 168 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 39 | 0.140 |
Why?
|
| Heart Atria | 2 | 2016 | 282 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 53 | 0.140 |
Why?
|
| Bioprosthesis | 1 | 2016 | 39 | 0.140 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 524 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 952 | 0.130 |
Why?
|
| Macrophages | 1 | 2019 | 578 | 0.130 |
Why?
|
| Cannula | 1 | 2016 | 50 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2016 | 120 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2019 | 860 | 0.130 |
Why?
|
| Subclavian Artery | 1 | 2015 | 43 | 0.130 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 98 | 0.130 |
Why?
|
| Length of Stay | 1 | 2019 | 743 | 0.120 |
Why?
|
| Prognosis | 3 | 2020 | 3785 | 0.120 |
Why?
|
| Atrial Appendage | 1 | 2015 | 33 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 316 | 0.120 |
Why?
|
| Random Allocation | 4 | 2020 | 327 | 0.120 |
Why?
|
| Comorbidity | 2 | 2015 | 952 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 73 | 0.110 |
Why?
|
| Aortography | 1 | 2014 | 65 | 0.110 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 16 | 0.110 |
Why?
|
| Contrast Media | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 51 | 0.110 |
Why?
|
| Amiodarone | 1 | 2013 | 14 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3465 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 1147 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 70 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 2763 | 0.110 |
Why?
|
| Thrombosis | 1 | 2016 | 301 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 39 | 0.110 |
Why?
|
| Dobutamine | 1 | 2013 | 61 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 2668 | 0.110 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 50 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 65 | 0.110 |
Why?
|
| Heart | 2 | 2020 | 574 | 0.100 |
Why?
|
| Software | 1 | 2017 | 667 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 253 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 113 | 0.100 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2012 | 7 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1498 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 691 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 166 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2014 | 283 | 0.100 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 38 | 0.100 |
Why?
|
| Labetalol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Metoprolol | 1 | 2011 | 15 | 0.100 |
Why?
|
| Vascular Resistance | 2 | 2024 | 103 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 156 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 836 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 105 | 0.090 |
Why?
|
| Catheters | 2 | 2021 | 83 | 0.090 |
Why?
|
| California | 2 | 2010 | 146 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 145 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 25 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 469 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 243 | 0.090 |
Why?
|
| Vasopressins | 1 | 2010 | 50 | 0.090 |
Why?
|
| Infliximab | 4 | 2013 | 159 | 0.090 |
Why?
|
| Drug-Eluting Stents | 1 | 2010 | 16 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 265 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 357 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 107 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2013 | 902 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 99 | 0.090 |
Why?
|
| Critical Illness | 1 | 2012 | 307 | 0.080 |
Why?
|
| Sirolimus | 1 | 2010 | 162 | 0.080 |
Why?
|
| Endothelin-2 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 8 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 365 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2010 | 475 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 141 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2016 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 354 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 725 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 498 | 0.080 |
Why?
|
| Chicago | 1 | 2013 | 1430 | 0.080 |
Why?
|
| Fatigue | 1 | 2008 | 173 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 129 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 95 | 0.070 |
Why?
|
| Selection Bias | 1 | 2007 | 36 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 785 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 141 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 234 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 30 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 806 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Observer Variation | 1 | 2007 | 613 | 0.060 |
Why?
|
| Metals | 1 | 2005 | 93 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 976 | 0.060 |
Why?
|
| Action Potentials | 1 | 2008 | 600 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 677 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1529 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 538 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 652 | 0.060 |
Why?
|
| Caspases | 1 | 2003 | 155 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 6368 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 227 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 241 | 0.050 |
Why?
|
| Spasm | 1 | 2022 | 17 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2015 | 395 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 38 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1862 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 88 | 0.050 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 34 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2020 | 155 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 496 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 4309 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 370 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1247 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 284 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 399 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 303 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 682 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 428 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.040 |
Why?
|
| Equipment Design | 1 | 2018 | 420 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 345 | 0.040 |
Why?
|
| Apoptosis | 1 | 2003 | 1717 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 68 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 484 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1673 | 0.030 |
Why?
|
| Oxygen | 1 | 2021 | 744 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 371 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 281 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 296 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 220 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 312 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2013 | 6 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 565 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 20 | 0.030 |
Why?
|
| Lidocaine | 1 | 2013 | 65 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 33 | 0.030 |
Why?
|
| Heart Arrest, Induced | 1 | 2013 | 29 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 90 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 193 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 98 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 158 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 145 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 661 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 51 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 221 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 305 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 606 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 82 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 358 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 153 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2008 | 4 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1903 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 276 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1877 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 223 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 848 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 975 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1073 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2006 | 55 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 242 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 25 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 33 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 899 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2003 | 60 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 152 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 472 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 640 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1598 | 0.010 |
Why?
|